These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 18344932)

  • 21. The influence of immunosuppression switching in liver function in adult hepatic transplantation.
    Marín Gómez LM; Loinaz Segurota C; Moreno González E; Moreno Elola-Olaso A; González-Pinto Arrillaga I; Meneu Díaz JC; Abradelo de Usera M; Gómez Sanz R; Jiménez Romero C; García Ureña MA; Vega Ruiz V
    Hepatogastroenterology; 2011; 58(106):532-5. PubMed ID: 21661426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.
    Biselli M; Andreone P; Gramenzi A; Lorenzini S; Loggi E; Bonvicini F; Cursaro C; Bernardi M
    Dig Liver Dis; 2006 Jan; 38(1):27-32. PubMed ID: 16311084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
    Toniutto P; Fabris C; Fumo E; Apollonio L; Caldato M; Avellini C; Minisini R; Pirisi M
    J Gastroenterol Hepatol; 2005 Apr; 20(4):577-82. PubMed ID: 15836706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S; Lyden E
    Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.
    Cescon M; Grazi GL; Cucchetti A; Vetrone G; Ravaioli M; Ercolani G; Morelli MC; Piscaglia F; Tamè M; Pinna AD
    Liver Transpl; 2009 Jul; 15(7):782-9. PubMed ID: 19562715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.
    Shergill AK; Khalili M; Straley S; Bollinger K; Roberts JP; Ascher NA; Terrault NA
    Am J Transplant; 2005 Jan; 5(1):118-24. PubMed ID: 15636619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
    Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
    Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
    Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis.
    Castedal M; Felldin M; Bäckman L; Olausson M; Friman S
    Transplant Proc; 2005 Oct; 37(8):3313-4. PubMed ID: 16298583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study.
    Lee EC; Kim SH; Park SJ
    Ann Transplant; 2018 Oct; 23():713-720. PubMed ID: 30310047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection.
    Kugelmas M; Osgood MJ; Trotter JF; Bak T; Wachs M; Forman L; Kam I; Everson GT
    Liver Transpl; 2003 Nov; 9(11):1159-65. PubMed ID: 14586876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation.
    Moreno Planas JM; Rubio Gonzalez E; Boullosa Graña E; Garrido Botella A; Barrios Peinado C; Lucena Poza JL; Jiménez Garrido M; Sanchez Turrion V; Cuervas-Mons Martinez V
    Transplant Proc; 2005 Jun; 37(5):2207-8. PubMed ID: 15964380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis.
    Rabie R; Mumtaz K; Renner EL
    Liver Transpl; 2013 Jan; 19(1):36-48. PubMed ID: 22821730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C: a case report.
    Yoshida Y; Ikegami T; Yoshizumi T; Toshima T; Yamashita YI; Yoshiya S; Shirabe K; Maehara Y
    Transplant Proc; 2014 Sep; 46(7):2426-9. PubMed ID: 25150603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human T-cell leukemia virus type I-associated myelopathy following living-donor liver transplantation.
    Soyama A; Eguchi S; Takatsuki M; Ichikawa T; Moriuchi M; Moriuchi H; Nakamura T; Tajima Y; Kanematsu T
    Liver Transpl; 2008 May; 14(5):647-50. PubMed ID: 18433046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholestatic hepatitis due to hepatitis C virus after a living donor liver transplantation.
    Kaneko J; Sugawara Y; Akamatsu N; Kokudo N; Makuuchi M
    Hepatogastroenterology; 2004; 51(55):243-4. PubMed ID: 15011874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha.
    Pan Q; Metselaar HJ; de Ruiter P; Kwekkeboom J; Tilanus HW; Janssen HL; van der Laan LJ
    Liver Transpl; 2010 Apr; 16(4):520-6. PubMed ID: 20373462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.